Back to search

Article

Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia

2025-06-14

Abstract excerpt

Aberrant activation of the RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In FLT3 -mutant AML, the selection of clones harboring heterogeneous RAS mutations drives resistance to FLT3 inhibitors (FLT3i). RAS activation is also associated with resistance to other AML targeted therapies, including the BCL2 inhibitor venetoclax. Despite the critical need...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
91ec14ff-7a7f-532d-be08-40f464e90683
DOI
10.1101/2025.06.10.658786
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaDOI 10.1101/2025.06.10.658786
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.Semantic proximity
Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in <i>FLT3-</i> and <i>KIT-</i> Mutant AMLSemantic proximity
Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in <i>FLT3</i> , <i>TP53,</i> and <i>MUC4</i> mutationsSemantic proximity
TP-0903 is active in models of drug-resistant acute myeloid leukemia.Semantic proximity
Anlotinib Induced Venetoclax-resistant Acute Myeloid Leukemia Stem Cells Apoptosis through Downregulating Mcl-1-mediated Anti-apoptoeic PathwaySemantic proximity
CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteinsSemantic proximity
Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemiaSemantic proximity
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Semantic proximity
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaSemantic proximity
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.Semantic proximity
Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical StudiesSemantic proximity
Select a neighboring publication to make it the new centre.